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REVIEW
Engineering Advanced In Vitro Models of Systemic 
Sclerosis for Drug Discovery and Development
Andrea De Pieri,* Benjamin D. Korman, Astrid Jüngel, and Karin Wuertz-Kozak*
DOI: 10.1002/adbi.202000168
1. Introduction
Systemic sclerosis (SSc; also termed scle-
roderma) is an autoimmune disease that 
is characterized by the distinctive patho-
genetic triad of microvascular dysfunc-
tion, dysregulation of innate and adaptive 
immunity, and generalized fibrosis in 
multiple organs.[1] SSc has the highest 
case-specific mortality of any of the auto-
immune rheumatic diseases, with more 
than half of patients dying as a direct 
consequence of the pathology.[2] For this 
reason, SSc is a disease with a high unmet 
clinical need. Although intensive research 
in the last years has improved the under-
standing of the disease, only one drug, 
nintedanib, has thus far been approved by 
the Food and Drug Administration (FDA) 
for the treatment of SSc-associated inter-
stitial lung disease.[3] Furthermore, there 
are no generally accepted therapies for skin and organ fibrosis, 
which are known to be key manifestations of SSc, leaving 
the need for novel antifibrotic therapeutic strategies in SSc.[4] 
Although significant strides have been achieved using various 
animal models, these systems are expensive for the purposes of 
routine drug development/screening studies and have limited 
replicability due to different physiology and genetics in com-
parison to the human disease.[5] These shortcomings of animal 
models impose the need for standardize protocols to increase 
reproducibility[6] and development of more reliable, clinically 
relevant in silico and in vitro models.[7]
In vitro cell-based studies have been proven to be valuable 
tools in drug discovery programs, especially due to their low 
cost and high speed of testing compounds. Cell cultures rep-
resents an immense value in the investigation of cellular and 
functional aspects of disease processes for improved thera-
peutic interventions.[8] The most commonly utilized model 
systems are based on conventional 2D monolayer cultures 
exposed to exogenous profibrotic stimuli, commonly trans-
forming growth factor-β (TGF-β).[9] However, customarily used 
cell-based models frequently fail to give predictable and reli-
able data for in vivo responses. A critical component of this 
failure results from the lack of recapitulating the native in vivo 
microenvironment. In the SSc scenario, the histopathological 
and physicochemical cues of the disease microenvironment are 
critical for the stimulation of biological functions mediated by 
cell signaling.[10] Multiple cytokines, chemokines, and signal 
transduction pathways are implicated in the progression of SSc 
as well as structural features of the extracellular matrix (ECM) 
such as stiffness, viscoelasticity, and topography. Moreover, 
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although 2D culture systems are simple and economical, they 
do not consider the spatial organization of cells within the 
3D architecture of organs and do not replicate native cell–cell 
and cell–ECM interactions and signaling pathways.[11] Recent 
advancements in 3D cell culture technologies and tissue engi-
neering strategies have made it possible to engineer advanced 
physiologically relevant 3D in vitro models not only to study 
disease mechanism and progression, but also to use as a plat-
form to design new therapeutic compounds and to screen for 
drug efficacy and safety.[12]
This review summarizes the utility and limitations of various 
animal models of SSc and focuses on the most recent advances 
in in vitro SSc models, highlighting the crucial role of bio-
logical, biochemical, and biophysical cues in mimicking SSc 
microenvironment. The potential of bioengineered tissues as in 
vitro models to investigate molecular and cellular mechanisms 
involved in the onset and progression of systemic sclerosis and/
or to serve as screening platforms to test novel pharmaceutical 
therapies for the treatment of the disease, will be discussed. In 
addition, we will shed light to the next challenges and future 
directions that must be addressed toward an effective 3D in 
vitro model for SSc.
2. Mechanisms and Pathophysiology of Systemic 
Sclerosis (SSc)
Systemic sclerosis is a complex chronic and often progressive 
disease characterized by vascular alterations, inflammation and 
autoimmunity, and multisystemic excessive fibrosis (Figure 1). 
Although skin fibrosis is the distinguishing hallmark, the 
pathological involvement of the viscera including the lungs, 
gastrointestinal tract, kidneys and heart determines the clinical 
outcome.[13] Patients are characterized by subtypes based on 
the extent of skin involvement, with limited cutaneous sys-
temic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis 
(dcSSc) subsets delineated on the basis of distal or proximal 
skin involvement.[14] The pathogenesis of systemic sclerosis is 
complex and remains elusive. An interplay between genetic fac-
tors and environmental events, such as job-related exposures to 
silica dust, vinyl chloride and organic solvents or viruses and 
other infectious agents, is likely to play a part in the origin of 
the disease.[15] The onset of vascular injury in SSc includes 
endothelial activation and vascular damage, thickening of the 
vessel wall due to intimal and smooth muscle cell proliferation, 
and finally vessel narrowing and obliteration, which lead to 
tissue ischemia, oxidative stress and ultimately organ dysfunc-
tion.[16] Infiltration of inflammatory cell within the lesions is 
common in patients with early-stage disease, and inflammatory 
and immune cells are an important source of profibrotic medi-
ators such as TGF-β, platelet-derived growth factor (PDGF), 
interleukin 1 (IL-1) and interleukin 6 (IL-6). Figure  2 depicts 
these multiple pathologic processes.
Dysregulation of both innate and adaptive immunity is also 
a prominent factor that contributes to systemic sclerosis patho-
genesis. Antinuclear antibodies are present in up to 95% of SSc 
patients and specific autoantibodies, such as antitopoisomerase 1, 
anticentromere, and anti-RNA polymerase III antibodies, directed 
against intracellular nuclear components, are present in over 75% 
of patients.[17] Besides the presence of autoantibodies, evidence of 
dysregulated immune responses are represented by inflamma-
tory cells and inflammatory molecules in target tissues such as 
the skin and lungs and a prominent type I interferon (IFN) signa-
ture in circulating and tissue-infiltrating immune cells.[18]
The pathologic hallmark of SSc is extensive fibrosis involving 
multiple organs, which can lead to significant organ failure.[19] 
Fibrosis is characterized by replacement of normal tissue archi-
tecture with rigid and mechanically stressed connective tissue 
Figure 1. Pathophysiology of SSc. Genetic and environmental factors trigger the onset of SSc. SSc is characterized by vascular alterations, inflammation and 
autoimmunity, and multisystemic excessive fibrosis, which ultimately lead to severe and life-threatening organ complications. Created with BioRender.com.
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rich in collagen and other ECM macromolecules, such as 
elastin, glycosaminoglycan, and fibronectin.[20] The abnormal 
accumulation of ECM results from increased synthesis by acti-
vated fibroblasts, enhanced assembly and deposition catalyzed 
by prolyl and lysyl-oxidase and transglutaminase 2 and aberrant 
ECM degradation.[21]
Figure 2. Molecular mechanisms of SSc. 1) Preclinical stage. Vascular injury is the earliest event in SSc which leads to endothelial cell activation and 
entrapment of peripheral blood mononuclear cells. 2) Inflammatory stage. Progressive vascular damage causes endothelial cell apoptosis, which in turn 
secrete ET-1 and PDGF that stimulate smooth muscle cell proliferation, leading to luminal narrowing, and inflammatory cells recruitment. Plasma cells 
secrete autoantibodies (anti-Scl-70, anticentromere, anti-RNA-polymerase III) and IL-6. Type 2 T helper (TH2) cells secrete TGF-β and IL-13. Polarized 
M2 macrophages secrete TGF-β. These soluble mediators contribute to fibroblasts activation and increase ECM deposition. 3) Late stage. Progressive 
endothelial cells apoptosis, smooth muscle cells proliferation and vessel narrowing lead to tissue hypoxia and oxidative stress which contribute to the 
maintenance of fibrosis. Fibroblasts undergo complete myofibroblasts differentiation and increase ECM deposition leading to mechanical stress and 
perpetuating the fibrotic process. M2 polarized macrophages infiltration further increases TGF-β secretion. Created with BioRender.com.
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The differentiation of fibroblasts into myofibroblasts is a 
critical step in the onset of fibrosis. Myofibroblasts are special-
ized fibroblasts that acquire characteristics of smooth muscle 
cells, including the expression of α-SMA. In contrast to physi-
ological wound healing, where myofibroblasts are present 
only transiently within granulation tissue before undergoing 
apoptosis, myofibroblasts in SSc are persistent. These con-
tractile cells secrete not only matrix proteins, but also TGF-β 
and other profibrotic components, and thus further promote 
ECM deposition and remodeling.[22] In addition to activation 
and proliferation of resident fibroblasts, other sources of acti-
vated fibroblasts include recruitment of circulating fibrocytes 
and the differentiation from epithelial cells.[23] Epithelial cells 
have been demonstrated to trans differentiate into fibroblasts 
and myofibroblasts, undergoing an epithelial to mesenchymal 
transition (EMT) in response to TGF-β and other growth fac-
tors and/or cytokines during the development of fibrosis.[24] 
In addition to epithelial cells, endothelial cells have also been 
shown to transdifferentiate into fibroblasts through endothe-
lial to mesenchymal transition (EndMT).[25] Other sources of 
fibroblasts include trans differentiation of pericytes and adipo-
cytes.[26] Scientific advances have considerably augmented the 
understanding of the pathophysiological mechanism of SSc. 
The antifibrotic drugs nintedanib and pirfenidone have been 
approved for the treatment of patients with idiopathic pulmo-
nary fibrosis, and nintedanib recently received approval for 
SSc-ILD, but there are still a dearth of effective anti-fibrotic 
agents for the full array of SSc manifestations.[27] There is 
therefore an urgent unmet need to develop new anti-fibrotic 
therapies for use in SSc.
3. Animal Models of SSc
Animals models have been extensively used to study the com-
plex mechanisms involved in the pathogenesis of SSc and ulti-
mately to bring new insight for the development of therapeutic 
strategies.
Recent years have seen a plethora of genetic, transgenics and 
induced animal models that have contributed to our knowledge 
of the initiating events of systemic sclerosis (Table 1).[28]
Genetic animal models spontaneously develop mutations to 
the genome with manifestations similar to those of SSc. One of 
the best-characterized genetic animal models of SSc are tight 
skin-1 (Tsk-1) mice, in which a tandem duplication in the gene 
for fibrillin 1 (Fbn1), a mediator of elastic fibers assembly, is 
responsible for the pathogenic phenotype. In heterozygous 
mice, this mutation leads to thickening of the subcutaneous 
tissue (hypodermis) and endothelial cell apoptosis. Fibrosis 
in these mice develops from excessive production of ECM by 
activated fibroblasts upon activation of the TGF-β pathway.[29] 
A related genetic model of SSc is tight skin 2 (Tsk-2) mouse, 
which presents mutations in the gene for type III collagen 
alpha.[30] Tsk-2 mice demonstrate increased type I and III col-
lagen, which lead to abnormal ECM deposition, and an inflam-
matory dermal mononuclear cell infiltrate.[31]
Transgenic mouse models with the pathological cascade of 
SSc have been established to further understand the process 
of the disease. The transgenic mouse model overexpressing 
the Fos-related antigen-2 (FRA-2) gene showed many of the 
important factors resulting in the vascular damage and pro-
gressive skin and lung fibrosis of systemic sclerosis as well 
as pulmonary hypertension.[32] A TNF-transgenic model was 
recently shown to develop spontaneous and severe pulmonary 
hypertension and have genomic overlap with SSc-PAH but 
to lack systemic fibrosis.[33] Another model is represented by 
urokinase-type plasminogen activator receptor (uPAR)-defi-
cient mice. Urokinase-type plasminogen activator receptor is 
a glycosylphosphatidylinositol-anchored cell surface receptor 
which concentrates its ligand, urokinase-type plasminogen 
activator (uPA), at the cell–matrix interface. The uPA/uPAR 
complex promotes the fibrinolysis and the degradation of 
other ECM, serving as a key regulator of ECM homeostasis 
and angiogenesis. uPAR deficient mice reproduce the fibrotic 
and vascular features of SSc, such as increase collagen con-
tent and perivascular inflammatory cells infiltration in skin 
and lungs.[34]
Inducible animal models are quicker and easier to evaluate 
than genetic models and offer valuable clues to study the role 
of selected target molecules in the developmental process of 
SSc. The bleomycin model of fibrosis is probably the most uti-
lized model of SSc. Bleomycin was originally isolated from the 
fungus streptomyces verticillus, and is often used as an anti-
tumor medication for the treatment of various kinds of malig-
nancy. Bleomycin hydrolase inactivates bleomycin by hydro-
lyzing the amide bond in the β-aminoalanineamide moiety. 
Bleomycin-induced toxicity occurs predominantly in the lungs 
and the skin, due to the deficiency of the enzyme in these 
organs.[35] For this reason, the bleomycin mouse model of 
fibrosis has been frequently used to replicate common features 
of SSc such as dermal or pulmonary fibrosis. Local dermal 
injections of bleomycin in mice induced collagen synthesis at 
the injection site over 4 weeks. The overall effects were found 
to be systemic because the lung similarly showed increased 
collagen synthesis.[36] Bleomycin can also be delivered via the 
intratracheal route, resulting in severe pulmonary fibrosis.[37] 
Although the bleomycin model replicates critical aspects 
observed in SSc, this model lacks the typical autoantibody pat-
terns present in the pathology and bleomycin induced fibrosis 
was found to be strain specific.[38] Another inducible animal 
models of SSc is represented by the hypochlorous mouse 
model (HOCl). Repeated intradermal injections of hypochlo-
rous acid generates hydroxyl radicals, which lead to enhanced 
synthesis of collagen in the lung and skin tissues. In addition, 
this model mimics the pathological damages observed in the 
systemic sclerosis kidneys and induces antitopoisomerase 
antibodies.[39] The mechanism of action of hypochlorous acid-
induced fibrosis is not fully understood, thus restricting its 
commonality of use. Another model is represented by the angi-
otensin II-inducible model of fibrosis. Angiotensin II (Ang II) 
is a vasoactive peptide that induces vascular constriction, water 
and salt retention, and high blood pressure.[40] Subcutaneous 
injection of Ang II
induced both inflammation and fibrosis in the skin by accu-
mulating activated fibroblasts and promoting EndMT of cir-
culating blood cells. However, it is not known whether these 
animal models developed autoantibodies specific for systemic 
sclerosis.[41]
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These animal models offer essential clues for the improved 
knowledge of the molecular mechanisms of SSc pathology and 
the identification of potential therapeutic targets for the treat-
ment of this disease.
As explained above, none of the currently available models 
encompasses all aspects of SSc in humans. Therefore, mul-
tiple models should be utilized when studying drug efficacy 
to account for deficiencies and limitations of single models, 
resulting however in high costs while not guaranteeing 
clinical translatability. In addition, although animal models 
predict biological relevant pharmacokinetic responses to 
drug administration, their different physiology and genetics 
from humans hamper the exact recapitulation of the human 
diseases.[28a] There have been numerous drugs which have 
been successful in animal models which have not performed 
well in clinical trials given the complexity of SSc and imper-
fection of each of the models.[42] The high number of ani-
mals required during preclinical studies remain an ethical 
issue, besides being cost-intensive and laborious.[43] Thus, it 
is becoming imperative the need to develop more predictable 
in vitro models that can mimic aspects of human in vivo cel-
lular behavior.
4. SSc: the Need for Advanced In Vitro Models
In the last few years, progress in the understanding of the 
pathogenesis of SSc energized the design of numerous prom-
ising clinical studies. Several recent reviews have summarized 
therapies for SSc that are currently in clinical trials and shed 
light on novel potential therapeutic targets for the manage-
ment of the disease.[44a,44b,4,44c,44d] For example, tocilizumab, 
a humanized monoclonal antibody against the human IL-6 
receptor-α, has shown encouraging results by improving both 
skin and lung fibrosis[45] and has reached phase III clinical 
trials. Another novel promising therapy is seen in trials of the 
endocannabinoid receptor type 2 agonist lenabasum. This syn-
thetic molecule has emerged as a potent modulator both of skin 
and lung inflammation have antifibrotic potential as well.[46] 
Nevertheless, despite the positive signs of clinical response in 
subsets of patients, these two clinical trials have been unsuc-
cessful in meeting their endpoints and failed to gain regulatory 
approval.[47,46] Furthermore, considering the emerging of new 
potential therapeutics, along with the repurposing of existing 
drugs, clinical trials in SSc are more active than ever. However, 
the limited numbers of patients available for trials poses the 
Table 1. Representative animal models of SSc.
Classification Model Pathological features Major limitations Refs.
Genetic Tight skin 1 (TSK-1) mouse model Skin fibrosis, antitopoisomerase-1 
autoantibodies
Dermal sclerosis is lacking, no sign of  
vasculopathy, absence of inflammation
[214]
Tight skin 2 (TSK-2) mouse model Skin fibrosis, mononuclear cell infiltration  
in the dermis and adipose tissues,  
antinuclear antibody
No sign of vasculopathy [215]
University of California at Davis line 200 
(UCD-200) chickens
Skin and organ fibrosis, perivascular  
lymphocytic infiltration, endothelial  
injury, antinuclear antibodies
Avian background limits molecular  
studies, high cost
[216]
Transgenic Fos-related antigen-2 (Fra-2) mouse model Skin fibrosis, microangiopathy, disease 
course similar to human SSc
Poor characterization, absence of 
autoimmunity
[217]
Endothelin-1 mouse model Glomerulosclerosis and interstitial fibrosis Absence of autoimmunity [218]
TGF-β receptor I transgenic  
mouse model
Collagen accumulation in dermis and 
pulmonary vessels, epidermal thinning, loss 
of adipose tissues in subcutis
Absence of autoimmune and 
 inflammatory aspects
[219]
Friend leukemia integration factor-1  
(Fli-1+/−) / Krüppel-like factor 5  
(KLF5+/−)
Fibrosis and vasculopathy of the skin and 
lung, B-cell activation and autoantibody 
production
Poor characterization,  
mild inflammation
[220]
Knockout Caveolin-1 KO mouse model Skin and lung fibrosis, vascular disease Mild inflammation and absence  
of autoimmunity
[221]
Fli-1 KO mouse Vascular disease, skin fibrosis Poor characterization,  
absence of autoimmunity
[222]
Induced Bleomycin mouse model of fibrosis (intra-
dermal injection)
Dermal or pulmonary fibrosis,  
antinuclear antibodies,  
inflammatory response
Fibrosis is limited to the injection site  
and not systemic, vascular  
phenomena are usually absent
[36]
Bleomycin rat model of fibrosis (intratra-
cheal injection)
Strong pulmonary fibrosis,  
antinuclear antibodies,  
inflammatory response
Fibrosis is limited to the lung site  
and not systemic, vascular  
phenomena are usually absent
[37]
Hypochlorous mouse model (HOCl) Dermal and pulmonary fibrosis,  
antitopoisomerase antibodies,
Poor characterization [223]
Sclerodermatous graft-versus-host  
disease (GVHD) mouse model
Dermal fibrosis and pulmonary,  
presence of inflammatory infiltrate
Sophisticated technical skills required [224]
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need to refine pre-clinical research in order to select the optimal 
drug candidates with the best chance of clinical success.
In light of the limitations associated with animal models, 
cell systems and in vitro tissue equivalents represents precious 
tools to investigate the disease’s molecular pathways and to 
generate a platform for drug screening for early-phase studies.
In vitro cell-based models are an important element of the 
drug discovery process. In contrast to cost-intensive animal 
models, assays using cultured cells are simple, fast, and cost-
effective as well as versatile and easily reproducible.[48] The 
efficacy of an in vitro model is determined by its capacity to 
closely replicate relevant characteristics of the in vivo microen-
vironment.[49] Different approaches can be utilized to develop in 
vitro models that recapitulate the SSc phenotype. One approach 
comprises the use of cells isolated from healthy donors, which 
are converted into a disease-specific phenotype by the addition 
of profibrotic modulators during the culture time to induce the 
expression and secretion of fibrotic markers and increase the 
deposition of ECM. Nevertheless, the use of exogenous stimuli 
does not result in a disease-activating mechanism. Due to short 
culture periods that do not model disease progression, cells do 
not acquire the full disease-specific patterns of gene expres-
sion and are fundamentally limited in representing the com-
plexity of the disease.[50] For this reason, cells derived from SSc 
patients have become one of the most important materials in 
the study of the pathology. For example, fibroblasts derived 
from SSc skin lesions have been demonstrated to secrete an 
abnormal amount of ECM proteins (collagens, fibronectin) and 
fibrogenic modulators (TGF-β, CTGF) and fibrotic markers 
(α-SMA) in vitro.[51] Despite the tremendous utility of patient-
derived cells, in vitro studies are limited by challenges including 
availability of patient donor cells, particularly in a rare disease 
such as SSc. In vitro expansion of scleroderma fibroblasts has 
been associated with loss of the SSc phenotype over time in 
culture, showing a marked decrease in collagen production in 
fibroblasts cultured for up to ten passages,[52] and a reduction 
of the disease transcriptional signature after four passages.[53] 
Moreover, patient-derived cells showed high heterogeneity with 
regard to inflammatory as well as fibrotic signatures, which 
can be lost during cell proliferation into any daughter lineage, 
leading to cell pools that do not recapitulate the variety of cells 
in vivo.[54] Therefore, especially given the complexity of SSc, it 
is imperative to achieve a system that allows for spatiotemporal 
control over the biological, biochemical, and biophysical cues of 
the in vitro extracellular microenvironment to properly mimic 
the pathological condition of SSc (Figure 3).
5. Biological Cues
5.1. Growth Factors Supplementation
A multitude of soluble growth factors are implicated in sys-
temic sclerosis (Table  2) and TGF-β is commonly recognized 
as the master regulator of fibrosis.[55] TGF-β belongs to a 
superfamily of proteins that includes bone morphogenetic pro-
teins (BMPs), growth differentiation factors (GDFs) activins, 
inhibins, myostatin, nodal and anti-Mullerian hormone (AMH) 
Figure 3. Overview of biological, biochemical, and biophysical cues used in vitro to recapitulate the SSc microenvironment. Created with BioRender.com.
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Table 2. Influence of growth factors on SSc phenotype and drug testing (α-SMA, α-smooth muscle actin; CTGF, connective tissue growth factor; 
ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; EndMT, endothelial-mesenchymal transition; ET-1, endothelin 1; FGF, fibroblast 
growth factor; FGFR, fibroblast growth factor receptor; IGF, insulin-like growth factor 1; IGF1R, insulin-like growth factor 1 receptor; JNK, c-Jun N-ter-
minal kinase; MCP-1, monocyte chemoattractant protein-1; MMP-1, matrix metalloproteinase-1; PDGF, platelet-derived growth factor; PI3K, phospho-
inositide 3-kinases; TGF-β, transforming growth factor-β; TKI, tyrosine kinase; VE, vascular endothelial; VEGF, vascular endothelial growth factor; 
ZO-1, zonula occludens-1 protein.
Soluble mediator Cell type Experimental output Therapeutics Refs.
TGF-βa) Primary human dermal fibroblasts TGF-β2 increased collagen I deposition Histone deacetylase inhibitor trichostatin A 
(TSA) inhibited the TGF-β-induced collagen I 
synthesis by suppressing Sp1 activity in skin 
fibroblasts
[225]
Human dermal fibroblast  
cell line (BJ)
TGF-β1 (25 ng mL-1) increased the expression  
of on collagen I, MMP-1 and CTGF and induced 
expression of α-SMA protein
S-adenosyl-l-homocysteine hydrolase (SAHH) 
inhibitor (DZ2002) reversed the  
stimulatory effect of TGF-β on collagen I, 
MMP-1 and CTGF expression
[226]
Human epidermal keratinocytes TGF-β (10 ng mL-1) induced EMT down-regulating 
E-cadherin and ZO-1 and upregulating vimentin  
and fibronectin
Smad inhibitor (SB431542)  
reversed established EMT
[227]
Microvascular endothelial cells 
(MVECs)
TGF-β (10 ng mL-1) induced EndMT synergistically  
with SSc-derived fibroblasts, reducing tube  
formation ability, CD31 and VEGF-A expression,  
and upregulating mesenchymal markers such as 
α-SMA, collagen I, and TGF-β
ET-1 dual receptor antagonists bosentan  
(BOS) and macitentan (MAC) reduced  
the expression of mesenchymal markers  
and restored CD31 expression and  
tube formation ability
[228]
SSc-derived human dermal microvas-
cular endothelial cells
TGF-β (10 ng mL-1) induced EndMT upregulating  
pro-collagen I and a-SMA and downregulating  
CD31 and VE-cadherin
– [99]
CTGF Human WI-38 lung fibroblasts cell 
line
CTGF (10 ng mL-1) showed augmented  
α-SMA levels
Inhibitors of Src-family kinases (SFK) and PI3K, 
blocked CTGF-dependent α-SMA upregulation
[229]
SSc-derived human dermal and lung 
fibroblasts
CTGF (40 ng mL-1) stimulated fibroblastic cell 
proliferation and increased collagen I and fibronectin 
deposition
– [230]
PDGF SSc-derived human dermal 
fibroblasts
PDGF (40 ng mL-1) stimulated the synthesis  
of collagen I
Dasatinib and nilotib (inhibitors of abl kinases 
and PDGF receptors) reduced the mRNA and 
protein levels of ECM proteins
[231]
SSc-derived human dermal 
fibroblasts
PDGF (10 ng mL-1 or 40 ng mL-1) stimulate the  
expression of MCP-1, which is associated with the 
presence of inflammatory infiltrates in SSc skin lesions
Antibodies blocking MCP-1 decreased the 
chemotactic activity of SSc fibroblasts
[232]
SSc-derived human dermal 
fibroblasts
PDGF-AA (10 ng mL-1) or PDGF-BB (10 ng mL-1) 
increased cell proliferation and ECM deposition
Crenolanib (inhibitor of PDGF receptor 
signaling) inhibited cell proliferation and 
migration
[233]
SSc-derived human dermal 
fibroblasts
PDGF-BB (40 ng mL-1) stimulated the synthesis  
of collagen I
Imatinib (tyrosine kinase inhibitor)  
blocked the stimulatory effects of PDGF  
in a dose-dependent manner
[234]
IGF SSc-derived lung fibroblasts IGF-II (100 ng mL-1 or 200 ng mL-1) induced  
collagen I and fibronectin deposition, without  
affecting fibroblasts proliferation
Inhibitors of PI3 kinase and JNK were  
able to block IGF-II-induced collagen  
and fibronectin production
[235]
Healthy and SSc-derived lung 
fibroblasts
IGF-II (200 ng mL-1) stimulated gene expression  
of fibronectin, collagen and α-SMA and  
decreased the expression of IGF-receptors  
and insulin receptor in SSc fibroblasts
Tyrphostin AG 538, a specific inhibitor  
of the IGF1R TKI, reduced intracellular c 
ollagen and fibronectin
[236]
FGF9 Human dermal fibroblasts FGF9 (10 ng mL-1) promoted the expression  
of collagen type I and α-SMA and the formation  
of stress fibers, as markers of fibroblast-to  
myofibroblast differentiation, by activating  
FGFR3 signaling
Treatment with the selective FGFR3 inhibitor 
PD173074 or knockdown of FGFR3 by siRNA 
abrogated the stimulatory effects of FGF9 on 
FGFR3 profibrotic target genes, and blocked 
FGF9-induced fibroblast activation
[237]
VEGF SSc-derived human dermal 
fibroblasts
VEGF (10 or 20 ng mL-1) showed direct profibrotic 
effects by upregulating procollagen I and III expression
– [238]
a)References serve as representative examples.
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proteins.[56] There are three isoforms of TGF-β (TGF-β1, TGF-
β2, and TGF-β3), which contain highly conserved regions but 
diverge in several amino acid regions. The three TGF-β iso-
forms function through the same receptor heterodimers, TGF-β 
receptor type 1(TGFR-1) and TGF-β receptor type 2 (TGFR2) 
and activate the same canonical mothers against decapenta-
plegic homologue (SMAD)-2–SMAD3 signaling pathway.[57] In 
this review we refer solely to the TGF-β family, and in particular 
to the TGF-β1 isoform, unless otherwise stated.
The bioavailability of TGF-β is regulated by its secretion from 
macrophages and other cells as an inactive precursor, which 
is then converted to its biologically active matrix-bound latent 
form via integrin-mediated processes.[58] TGF-β is a master 
regulator of fibroblast phenotype and function. Upon TGF-β 
stimulation, fibroblasts are become activated and undergo phe-
notypic transition into myofibroblasts, which leads to excessive 
matrix deposition and unbalance between matrix synthesis/
degradation signals.[59] Furthermore TGF-β plays an important 
role in the EMT of epithelial cells to myofibroblasts.[24,60] In 
addition, TGF-β can play a role in the vasculopathy observed 
in SSc. TGF-β stimulates the expression of vascular endothe-
lial growth factor (VEGF) and endothelin-1 (ET-1) in endothelial 
cells,[61] thereby mediating the vasoconstriction seen in patients 
with SSc.[62] Thus, the complex effects of TGF-β on proangio-
genic and antiangiogenic factors partially explain the complex 
vascular phenotype seen in patients with SSc. The delivery 
of TGF-β to in vitro fibrosis platforms is a critical element in 
studying fibrotic mechanisms. The delivery in vitro is generally 
performed by simple addition of soluble TGF-β to the culture 
medium. For instance, studies proved that the supplementation 
of TGF-β to human skin fibroblasts increased the deposition 
of collagen type I.[63] In response to the need for an effective 
therapeutic for dermal fibrosis, a plethora of TGF-β stimulated 
in vitro models have been used as screening platform for anti-
fibrotic molecules. As one example of many, human dermal 
fibroblasts stimulated with TGF-β1 to induce differentiation 
into profibrotic myofibroblast cells were used to assess the anti-
fibrotic potential of Pirfenidone (PFD), a synthetic molecule 
already FDA-approved for the treatment of idiopathic pulmo-
nary fibrosis. It was shown that PFD inhibited fibrogenic sig-
nals of TGF-β by abrogating p38-mediated MAPK activation, 
downregulating the transcription of profibrotic genes, such as 
type I and type III collagen, and blocking myofibroblast differ-
entiation.[64] One of the limitations of this approach consists in 
the fact that the bioavailability of TGF-β in vivo is controlled 
by ECM-mediated integrins and mechanosensing mechanisms 
that inhibit or activate its binding to the corresponding recep-
tors. Therefore, the development of culture conditions with 
tailored (patho-) physiological substrate stiffness could better 
mimic TGF-β in vivo bioavailability and may advance the rel-
evance of its use in vitro culture models.[65]
Another critical growth factor involved in the pathogenesis 
of SSc is connective tissue growth factor (CTGF). CTGF is a 
cysteine-rich matricellular protein that functions in combina-
tion with TGF-β to enhance fibrotic responses. CTGF is not 
normally expressed in dermal fibroblasts, but is constitutively 
overexpressed by fibroblasts present in skin and pulmonary 
fibrotic lesions of scleroderma patients. The overexpression 
of CTGF promotes fibroblast proliferation, myofibroblast 
differentiation, and matrix deposition.[66] Moreover, CTFG plays 
a role in leading endothelial cells to transdifferentiate toward 
myofibroblasts.[67] Supplementation of CTGF in the culture 
media was showed to stimulate fibroblastic cell proliferation 
and ECM synthesis.[68] A recent study demonstrated that knock-
down of CTGF using a mesoporous silica nanoparticle-based 
small interfering RNA (siRNA) delivery system prevented col-
lagen deposition, activation and differentiation of fibroblast.[69]
Platelet-derived growth factors (PDGFs) have been demon-
strated to have a critical role in fibrosis. PDGF is secreted by 
platelets, endothelial cells, macrophages, and fibroblasts that 
function as potent mitogens and chemoattractants for mesen-
chymal progenitor cells.[66a] Elevated expression of PDGF and 
its receptors has been found in scleroderma skin and lung tis-
sues, and contributes to persistent fibrosis by the generation of 
reactive oxygen species and consequent fibroblast activation.[70] 
The supplementation of PDGF to normal human dermal fibro-
blasts in vitro has been shown to increase the mRNA and pro-
tein levels of matrix metalloproteinase 1 (MMP-1) and tissue 
inhibitor of metalloproteinase (TIMP)-1, but not type I collagen, 
fibronectin, or TIMP-2. Additionally, PDGF induced the mito-
genic and migratory activity of human dermal fibroblasts in a 
dose-dependent manner.[71]
Another important mediator involved in the pathogenesis of 
SSc is endothelin 1 (ET-1). Endothelins are potent vasomodu-
latory peptides produced by endothelial cells, macrophages, 
fibroblasts and other cell types and can function as downstream 
mediators of TGF-β responses.[72] ET-1 signaling via endothelin 
receptors A (ETRA) and B (ETRB) on fibroblasts induces fibro-
blast migration and myofibroblast differentiation. Primary 
cultured dermal fibroblasts from SSc patients and healthy con-
trols treated with ET-1 upregulated collagen type I, CTGF, type 
I plasminogen activator inhibitor (PAI-1) and pAkt in a time-
dependent manner within 72 h.[73] In addition, the synergistic 
treatment of endothelial cells isolated from patients with SSc 
with ET-1 and TGF-β induced activation of the endothelial to 
mesenchymal transition (EndMT) process. Treatment with 
macitentan (MAC), an ET-1 receptor antagonist which is clini-
cally used in pulmonary hypertension, prevented EndMT and 
fibroblast accumulation.[74]
It is worth to note that, due to the multifactorial nature of 
SSc, a multitude of interconnected growth factor-activated 
molecular pathways occur across multiple tissues, leading to 
aberrant signaling crosstalk (which includes also cytokines, 
chemokines, adipokines, neurotrophins, and metabolites) and 
ultimately to organ alterations. For this reason, results obtained 
in vitro from individual cell populations exposed to single 
growth factors need to be treated with caution, representing 
only a minimal fraction of SSc complexity.
5.2. Cytokines Supplementation
A wide range of cytokines have been found to be potent regu-
lators of tissue fibrosis and endothelial damage.[75] The inter-
leukin (IL)-1 family is a group of 11 proinflammatory and 
anti-inflammatory cytokines that have been reported to be 
involved in the pathogenesis in SSc. For example endogenous 
IL-1α expression by SSc fibroblasts has been demonstrated to 
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increase the expression of IL-6 and PDGF, determining the 
abnormal function of SSc fibroblasts.[76] IL-6 is a pleiotropic 
and pro-inflammatory cytokine that is produced by activated 
immune cells and stromal cells, including T cells, macrophages, 
endothelial cells and fibroblasts, and is associated with a wide 
range of biological functions.[77] In particular, IL-6 is a potent 
inducer of matrix production in fibroblasts by increasing TGF-β 
expression, TIMP-1 synthesis and myofibroblast differentiation, 
resulting in collagen accumulation.[78] Treatment with anti-
IL-6 therapy (tocilizumab) modified the biological characteris-
tics of dermal fibroblasts derived from SSc patients, restoring 
functional properties, and reversing TGF-β-activated molecular 
pathways which were present prior to treatment.[79] IL-4 is a 
type 2 cytokine activated by CD4+ and CD8+ T cells and mast 
cells.[80] IL-4 has been demonstrated to be a profibrotic cytokine 
participating in cutaneous, cardiac fibrosis, pulmonary fibrosis, 
and hepatic fibrosis. IL-4 supplementation was shown to induce 
fibroblasts proliferation, myofibroblasts differentiation and col-
lagen production in vitro.[81] IL-13 is another type 2 cytokine 
that is increased in the serum and lesional tissue of patient 
affect by SSc.[82] Supplementation of primary dermal fibroblasts 
with IL-13 stimulated cell proliferation and ECM synthesis.[83] 
IL-17 has been reported to be increased in the peripheral blood 
and target organs, including skin. It amplifies inflamma-
tory responses by inducing the production of IL-6, CCL2 and 
CXCL8 (IL-8), MMPs and the expression of adhesion molecules 
in stromal cells including fibroblasts and endothelial cells.[84] 
Supplementation of IL-17 enhanced the proliferation of dermal 
fibroblasts and induced the expression of adhesion molecules 
and IL-1 production in endothelial cells in vitro.[85] TNF-α is a 
proinflammatory cytokine which has been reported to be ele-
vated in patients with SSc and favors the development of pul-
monary fibrosis and pulmonary arterial hypertension.[86] TNF-α 
supplementation induced high levels of IL-6 in SSc-derived 
fibroblasts, participating in the self-perpetuation of inflamma-
tion during SSc.[87]
In summary, a myriad of soluble mediators is involved in 
the pathogenesis and progression of SSc, which are secreted by 
several cell populations according to the stage of the disease. 
In order to properly supplement these molecules in vitro, con-
tinued efforts to understand native pathophysiological sign-
aling pathways will be necessary. This requirement will help 
to recapitulate the concentrations and spatial and temporal dis-
tributions of bioactive factors during these processes. To date, 
biomaterial-based GF delivery systems have been optimized 
to provide differential immobilization efficiency and release 
kinetics.[88] While these systems have been extensively used 
in regenerative medicine, we also foresee their utility for the 
design of in vitro SSc models.
5.3. Serum Supplementation
The beneficial effect of animal sera has long been recognized 
as means to promote in vitro cell attachment, expansion, main-
tenance, and proliferation by providing essentials nutrients 
and growth factors.[89] However, animal derived sera, such as 
fetal bovine serum (FBS) or fetal calf serum (FCS), have sev-
eral technical disadvantages associated with to batch-to-batch 
variation, xenoimmunization, and possible contamination 
with mycoplasma, viruses, endotoxins, and prions.[90] These 
limitations can affect the phenotype and the behavior of cells 
expanded in culture, preventing a quality-by-design approach.[91] 
Human-derived sera can replace FBS and FCS supplemented 
media and can create an in vitro microenvironment that more 
accurately resembles the human environment.[92] It has been 
demonstrated that human dermal fibroblasts viability cultured 
in human serum (HS) supplementation was much higher 
compared to FBS supplementation. Furthermore, gene expres-
sion analysis showed that fibroblasts cultured with HS supple-
mentation maintained expression of collagen type I, increased 
expression of collagen type III and fibronectin, and reduced 
expression of a-smooth muscle actin (a-SMA) compared to 
FBS.[93] Serum derived from patients affected by SSc has been 
demonstrated to contain characteristic serum autoantibodies, 
profibrotic chemokines and growth factors such as IL-4, IL-17, 
and CTGF, and sonic hedgehog (SHH), which stimulate 
fibroblast-to-myofibroblast transition and promote dermal 
fibrosis.[94] In addition, a recent study identified a discriminant 
metabolic profile between the serum derived from patients 
affected by SSc and healthy patients, suggesting the impor-
tance of SSc serum not only as a diagnostic tool for the diag-
nosis and classification of the disease.[95] Very few studies have 
thus far investigated the effect of SSc sera in vitro. In particular, 
immune complexes containing scleroderma-specific autoanti-
bodies derived from patients’ serum, have been showed to elicit 
proinflammatory and profibrotic effects in skin fibroblasts.[96] 
Another study demonstrated that autoantibodies purified 
from SSc-patient sera directed to platelet-derived growth factor 
receptor (PDGFR) were able to induce growth and a pro-fibrotic 
state in vascular smooth muscle cells through the epidermal 
growth factor receptor (EGFR).[97] Another study showed that 
H2O2 production by endothelial cells and fibroblasts was higher 
after incubation with SSc sera than with healthy sera. Moreover, 
this model allowed to test the efficacy of bosentan and N-ace-
tylcystein potentiated 5-fluorouracil (5FU) on the inhibition of 
oxidative stress.[98] Treatment with SSc sera has been reported 
to induce EndoMT of dermal microvascular endothelial cells by 
reducing the expression of endothelial markers such as CD31 
and VE-cadherin, and upregulating of mesenchymal markers, 
including α-SMA and collagen type I.[99]
Despite these interesting results on the use of patient-derived 
serum in cell culture, a limited number of investigations have 
assessed the potential of SSc serum as a tool to recreate the 
pathological microenvironment in vitro.
5.4. Cocultures
In the native tissue milieu, various cell populations interact 
between each other, stimulating different signaling pathways, 
and thus influencing numerous aspects of cell function. In 
vitro coculture models have been developed to recapitulate the 
in vivo physical contact and paracrine signaling between cell 
types. Coculture systems can be carried out either by directly 
seeding different cell types together in the same culture dish, 
or indirectly, using transwell inserts, whereby cells are located 
in the same media, without being in contact.[100] Multiple cell 
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types, including epithelial cells, fibroblasts, endothelial cells, 
pericytes and leukocytes respond to noxious stimuli in the 
pathogenesis of SSc. Several in vitro models have been estab-
lished to investigate the effect of complex intracellular inter-
actions during pathogenic events. For example, in order to 
elucidate the influence of SSc epidermal keratinocytes on 
dermal fibroblasts, dispase-dissociated epidermal layers were 
directly cocultured within a collagen-embedded fibroblast gel. 
Results showed that SSc epidermal sheets strongly stimulated 
fibroblast activation, causing gel contraction and induction of 
CTGF via IL-1, ET-1, and TGF-β. The addition of exogenous IL-1 
receptor antagonist (IL-1ra) blocked gel contraction by SSc epi-
dermis, suggesting a potential therapeutic implication.[101]
Another study investigated the effect of dermal fibroblasts 
in the impairment of angiogenesis in SSc. By oversecreting 
pigment epithelium-derived factor (PEDF), a major antiangio-
genic factor, SSc-derived fibroblast suppressed tube formation 
when cocultured with human dermal microvascular endothelial 
cells (MVECs) in an angiogenesis in vitro assay. PEDF knock-
down in SSc fibroblasts reversed this process and rescued the 
number of tubule formed by MVECs. This pathway may pre-




Tissue hypoxia is a characteristic feature of SSc and con-
tributes directly to the progression of the disease.[103] It was 
demonstrated that fibrotic lesions in the skin of SSc patients 
exhibit significantly decreased oxygen levels in comparison to 
SSc nonfibrotic skin and the skin of healthy individuals.[104] 
Molecular responses to hypoxia are regulated by the transcrip-
tion factor hypoxia-inducible factor 1 (HIF-1). While HIF-1 is 
rapidly degraded after translation under normoxic conditions, 
its activity increases exponentially after exposure to low oxygen 
levels. The activation of HIF-1 thus plays a critical role in the 
transcriptional activation of downstream signaling involved 
in cell proliferation, angiogenesis and fibrogenesis.[105] Tissue 
oxygenation in SSc is impaired by microvascular alterations 
and reduced capillary density, which result in a decrease of the 
blood flow and poor oxygen supply.[104,106] Oxygen supply is fur-
ther reduced by accumulation of ECM, which impairs diffusion 
from blood vessels to cells.[107] Chronic tissue hypoxia causes a 
vicious cycle by overexpression of VEGF, which in turn leads 
to aberrant vessel formation and TGF-β activation, thereby 
increasing tissue fibrosis.[108] Hypoxia induces multiple ECM 
proteins in dermal fibroblasts in vitro, such as thrombospondin 
1, collagens, fibronectins, insulin-like growth factor binding 
proteins, and transforming growth factor β-induced protein, in 
a time-dependent manner.[109]
Numerous studies have contributed to the understanding 
of the role of hypoxia on the molecular mechanism of SSc. 
For instance, it has been showed that dermal fibroblasts stim-
ulated with hypoxia (1% oxygen tension) showed increased 
CTGF expression via activation of HIF-1α, contributing to the 
progression of fibrosis.[110] Hypoxia can also drive epithelial-
mesenchymal transition (EMT). It was demonstrated that severe 
hypoxia (1.5% oxygen tension) as well as moderate hypoxia (3% 
oxygen tension) induced the expression of α-smooth muscle 
actin (α-SMA) and vimentin and decreased the expression of 
E-cadherin in alveolar epithelial cells (AEC). In addition, hypoxia 
increased the levels of TGF-β, and preincubation of cells with 
an inhibitor of the TGF-type I receptor kinase prevented the 
hypoxia-induced EMT, suggesting that the process was TGF-β 
dependent.[111] Therapeutic strategies targeting hypoxia have 
been tested in vitro. 2-Methoxyestradiol (2-ME), a potent inhib-
itor of HIF-1α, inhibited the fibrotic effect of hypoxia on SSc 
fibroblasts by down-regulating CTGF and collagen I through 
the PI3K/Akt/mTOR/HIF-1α signaling pathway. In addition, 
2-ME induced apoptosis and inhibited proliferation of SSc fibro-
blasts.[112] Despite the importance of hypoxia in SSc, conven-
tional in vitro conditions expose the cells to a non-physiological 
hyperoxic environment (20% oxygen tension) that is far from 
recapitulating the pathological microenvironment.
6.2. Reactive Oxygen Species
Oxidative stress, as defined by an imbalance between oxi-
dants (reactive oxygen and nitrogen species (ROS/RNS) and 
antioxidants, is consistently observed in patients with SSc.[113] 
Unpaired electrons make free radicals highly reactive and 
among them, the superoxide radical (·O2
−), hydrogen peroxide 
(H2O2), hydroxyl radical (·OH
−), hypochlorous acid (HOCl) and 
peroxynitrite (ONOO−) are key oxidative molecules within the 
ROS family.[114] Several oxidative stress biomarkers, such as 
nitric oxide, malondialdehyde (MDA-a marker of lipid peroxy-
dation), asymmetric dimethylarginine (ADMA) and hydroper-
oxides are elevated in the blood of SSc patients compared to 
healthy controls.[115] Oxidative stress has been demonstrated 
to cause the activation and damage of ECs, leading to vas-
cular hyperreactivity, apoptosis and impaired angiogenesis.[116] 
Increased ROS generation has been reported to mediate 
TGF-β-induced EndMT.[117] ROS have been shown to support 
chronic inflammation and autoimmunity through the genesis 
of neoepitopes and the activation of T and B lymphocytes and 
macrophages.[118] Permanent overproduction of ROS stimulates 
the proliferation and activation of fibroblasts and their syn-
thesis of ECM.[119] Also, fibroblasts from SSc have been shown 
to maintain an overproduction of ROS in SSc through the 
upregulation of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (NOX)-2 and NOX-4 proteins.[120] NOX is a 
family of enzymes involved in the generation of ROS, acting 
via the transfer of a single electron from NADPH to oxygen.[121] 
The activation of NOX has been demonstrated to trigger fibro-
blast proliferation and expression of type I collagen genes in 
SSc cells, thereby maintaining an autocrine feedback mecha-
nism of ROS generation.[119]
As oxidative stress impacts many aspects of the pathophysi-
ology of SSc, several in vitro studies assessed the potential of 
natural and synthetic antioxidants in the supportive treatment 
of SSc. The antioxidant epigallocatechin-3-gallate (EGCG), 
a polyphenol present in green tea extracts, has been shown 
to reduce oxidative stress and the fibrotic effects on activated 
dermal fibroblasts from SSc patients.[122] The antioxidant effect 
Adv. Biology 2021, 5, 2000168
www.advancedsciencenews.com
© 2021 The Authors. Advanced Biology published by Wiley-VCH GmbH2000168 (11 of 26)
www.advanced-bio.com
of kaempferol, a natural flavonoid, was investigated on H2O2-
induced intracellular ROS accumulation in SSc fibroblasts and 
suppressed the intracellular accumulation of ROS and reduced 
H2O2-induced apoptosis.
[123] N-acetylcysteine (NAC), a scav-
enger of free radicals and a precursor of the major antioxidant 
glutathione, inhibits fibroblast proliferation and collagen syn-
thesis[119] and reduces peroxynitrite (ONOO−) synthesis by acti-
vated lung macrophages from SSc patients in vitro.[124]
Although ROS seem to have an important role in fibrosis, a 
therapeutic strategy utilizing antioxidants is not yet clear and 
further investigations are needed to further elucidate the mech-
anisms linking ROS dynamics and SSc pathogenesis.
7. Biophysical Cues
7.1. Substrate Stiffness
In addition to biological and biochemical signals, the dysreg-
ulation of biophysical properties of the tissue microenviron-
ment in skin, lung, and other organs have been associated 
with the progression of fibrosis in SSc.[125] Excessive depo-
sition of ECM increases tissue stiffness and reduces the 
elasticity of affected organs, leading to mechanical stress 
(Table  3).[126] Tissue stiffness can be measured as the elastic 
modulus, defined as the resistance to deformation, and 
expressed as the magnitude of a stress (compression, elonga-
tion, or shear force, normalized to area) divided by the strain 
(deformation) induced by the stress.[127] Increased matrix stiff-
ness anticipates the development of fibrosis, which suggests 
that tissue stiffening may induce the early activation of myofi-
broblasts.[4] Matrix stiffness orchestrates fibrosis by controlling 
fundamental profibrotic mechanisms including mechano-
activation of myofibroblasts via mechano-transduction path-
ways. Mechano-transduction involves cell surface integrins 
and changes in cytoskeletal tension mediated by focal adhe-
sion kinase (FAK) and RHO-associated kinase (ROCK). These 
signals activate the downstream effectors YAP (Yes-associated 
protein), TAZ (transcriptional coactivator with PDZ-binding 
motif ) and myocardin-related transcription factor (MRTF) 
which increase fibroblast activation and further perpetuate 
the fibrotic process (Figure  4).[128] Lung fibroblasts cultured 
on stiff substrates showed an increase in proliferation and 
differentiation into myofibroblasts in comparison to soft sub-
strates.[129] Moreover, high substrate stiffness increased the 
synthesis of ECM and the expression of α-SMA and decreased 
the expression of matrix proteolytic genes and prostaglandin 
E2 (PGE-2).[129] The increase in myofibroblasts’ contractility 
leads to further matrix remodeling and stiffening and activa-
tion of TGF-β, amplifying the signal and leading to a positive 
feedback loop.[130] TGF-β1 is secreted and stored in the ECM in 
a latent multiprotein complex with latency associated peptide 
(LAP) and latent TGF-β1 binding proteins (LTBPs).[131] The 
activation of TGF-β1 first requires the binding of αv integrin 
to arginine-glycine-aspartic acid (RGD) sequences in LAP.[132] 
Mechanical forces exerted by cells on LAP via integrin-based 
adhesions then lead to changes in the conformational state of 
this complex, which ultimately release and activate TGF-β1 for 
receptor binding.[133]
Culture systems with tailored mechanical properties have 
been engineered to mimic aspects of diseased tissues and inves-
tigate the mechanism of myofibroblast activation. For instance, 
stiff collagen hydrogels promoted stress fibers formation, 
smooth muscle actin (SMA) expression and TGF-β1-induced 
response in human fibroblasts.[134] Another study identified that 
a stiff polyacrylamide substrate induced lung myofibroblast dif-
ferentiation through actin cytoskeletal remodeling-mediated 
activation of megakaryoblastic leukemia factor-1 (MKL1), which 
transduces mechanical stimuli from the ECM, leading to the 
induction of a fibrogenic program.[135] A recent study showed 
that the activity of the transient receptor potential vanilloid 4 
(TRPV4) channel was increased when cells were plated on stiff 
collagen-coated polyacrylamide gel matrices within the patho-
physiological range seen in diseased/fibrotic dermal tissue. 
Genetic ablation or pharmacological antagonism of the TRPV4 
channel abrogated Ca2+ influx and matrix stiffness-induced 
myofibroblast differentiation, evidencing that therapeutic inhi-
bition of TRPV4 activity may provide a targeted approach to the 
treatment of scleroderma.[136]
Given the increasing recognition that ECM stiffness is a 
major factor contributing to the progression of SSc, it has 
become evident that the identification of optimal substrate 
stiffness which replicates pathological fibrotic conditions 
will enable the development of more precise mechano-thera-
peutic interventions for tissue stiffening. Therapeutic strate-
gies targeting mechanotransduction signaling mediated by 
integrins,[132b] FAK,[137] ROCK,[138] or YAP/TAZ[139] have been 
promisingly tested in preclinical and clinical studies.
7.2. Substrate Topography
The topographical organization of the ECM significantly influ-
ences cell morphology and behavior, including growth, adhe-
sion, and migration.[140] Cells sense their underlying topography 
via focal adhesion interactions, pushing and pulling against 
the matrix and activating a cascade of cellular and molecular 
events, which ultimately influence gene and protein expres-
sion.[141] Morphological changes to the dermal collagen organi-
zation and focal adhesion complexes have been reported in skin 
biopsies from SSc patients. These changes are characterized by 
the presence of highly aligned collagen bundles, and a loss of 
normal “basket-weave” collagen organization that is character-
istic of the healthy dermis.[142] The alteration of the stiffness of 
the ECM significantly contributes to the alignment of the col-
lagen fibrils, and further amplifies the fibrotic process.[143] The 
ability of cells to mechanically sense these changes may be due 
to the deposition and realignment of new collagen fibrils in 
which cells generate myosin-generated tensile forces applied 
through cell–matrix adhesions.[144] In vitro studies have demon-
strated that increasing stress fiber formation and ECM align-
ment increase the elastic modulus of the fibroblast-populated 
collagen gels over a culture period of 21 d.[145] Moreover, several 
studies have reported that mechanical strength of anisotropic 
nanofibers is significantly higher than that of the disordered 
nanofibers.[146] The anisotropic ECM ultrastructure within the 
fibrotic microenvironment is a critical cue in maintaining the 
myofibroblasts phenotypes in SSc. This was demonstrated by 
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using a 3D model of either randomly oriented or aligned elec-
trospun poly-caprolactone (PCL) nanofibers with adsorbed 
type I collagen. Guidance cues from aligned collagen fibers 
enhanced the fibrogenic potential of dermal fibroblasts by 
increasing cell migration, adhesion, and guidance signaling 
pathways. Arhgdib (Rho GDP-dissociation inhibitor 2) was one 
of the most upregulated genes following fibroblast culture on 
aligned fiber substrates, and siRNA knockdown of Arhgdib 
Table 3. Influence of substrate stiffness on the fibrotic phenotype in SSc and drug testing (α-SMA, α-smooth muscle actin; DFs, dermal fibroblasts; 
EKs, epidermal keratinocytes; IPF, idiopathic pulmonary fibrosis; MRTF-A, myocardin-related transcription factor A; PAAm, polyacrylamide; PDMS, 
polydimethylsiloxane; PI3K, phosphoinositide 3-kinases; TAZ, transcriptional coactivator with PDZ-binding motif; TCP, tissue culture plastic; TGF-β, 
transforming growth factor-β; YAP, yes-associated protein).
Model Cell type Experimental output Therapeutics Refs.
PAAm gels with moduli of 0.6 
(healthy tissue) or 6 kPa (sclerotic 
tissue)
Healthy and SSc-derived human 
DFs
High substrate stiffness led to a  
pronounced increase in TAZ/YAP  
nuclear localization and increase in the 
number and size of actin stress fibers 
indicative of a fibrotic transition
Dimethyl fumarate (DMF), via inhibition 
of the PI3K/Akt pathway, reduced  
nuclear localization of both YAP and TAZ 
in fibroblasts on stiff gels. In addition, 
it reduced the cell spread area and the 
number and size of stress fibers
[139]
Soft (5 kPa) and stiff (50 kPa) col-
lagen coated PAAm gels
Healthy and SSc-derived human 
DFs
High substrate stiffness enhanced  
nuclear translocation of MRTF-A in  
dermal fibroblasts. The SSc cells had  
more nuclear MRTF-A on soft and stiff 
matrices than healthy control cells.  
Collagen expression and synthesis 
increases on stiffer matrices
Inhibitor of nuclear translocation  
of MRTF-A (CCG-1423) or knockdown  
of MRTF-A reduces contractility  
and suppresses fibrotic targets in SSc 
fibroblasts
[239]
PDMS substrates with varying stiff-
ness to mimic healthy (1–10 kPa) 
and fibrotic (15–50 kPa) dermis
Primary adult human DFs Cells cultured on skin-soft silicones  
were α-SMA-negative and displayed low 
mRNA levels of fibrosis-associated genes. 
Cells grown on 50 kPa and on TCP had 
α-SMA-positive stress fibers
– [145]
Collagen-coated PAAm hydrogels 
with compliant (0.5 kPa) or stiff (12 
kPa) matrices
Normal human primary EKs NHEKs grown on soft matrix expressed 
more E-cadherin and less α-SMA than 
cells grown on stiff matrix. Stiff matrix 
augmented the TAZ protein expression 
level compared to soft matrix
Transient receptor potential  
vanilloid 4 (TRPV4) antagonist  
(GSK219) blocked both matrix stiffness-
induced and TGF-β-induced expression  
of YAP and TAZ proteins
[240]
Collagen I-coated PAAm gels of 
elastic moduli 0.4 kPa (healthy lung 
tissue) and 25 kPa (fibrotic lung 
tissue)
Normal IPF- pulmonary derived 
fibroblasts
Cells exhibited predominant nuclear  
localization of YAP/TAZ on stiff  
matrix and far fewer cells exhibiting  
distinct nuclear localization on  
soft matrix
YAP and TAZ siRNA knockdown  
attenuates profibrotic matrix  
synthesis, contraction, and proliferation, 
preferentially on pathologically  
stiffened matrices
[128a]
Engineered microtissue based on 
micropillar device
Normal human lung fibroblasts Stiffness of TGF-β1 treated microtissues 
was higher (24.0 ± 8.0 kPa) than  
untreated microtissues (5.5 ± 2.8 kPa)  
and matched those of fibrotic lungs
Nintedanib and pirfenidone strongly  
inhibited TGF-β1-induced tissue  
stiffening and maintained tissue  
stiffness and compliance comparable to 
untreated samples
[241]
Silicone culture substrates with tun-
able Young’s modulus (5–47 kPa)
Rat lung myofibroblasts (MFs) Induction of MF contraction with 
thrombin enhanced latent TGF-β1 activa-
tion on 9–47-kPa substrates but had no 
effect on 5-kPa soft substrates. Increased 
α-SMA expression on stiff (47 kPa) 
substrates
– [130]
Collagen I-coated PAAm gels of 
various stiffnesses (1, 2, 8, 25, or 
50 kPa)
Normal human lung fibroblasts Expression of α-SMA proteins was  
higher on the stiffer substrates  
(25 kPa gel and TCP) than on the soft  
2 kPa gel. Migration of fibroblasts on 
stiff substrates was higher than cells on 
2 kPa gel
Short interfering RNA for α-SMA  
inhibited cell migration
[242]
Gelatin-coated PAAm gels with a 
stiffness of 13 kPa
Mesenchymal-like cells generated 
from iPSCs
Cells were highly proliferative, showing 
increased gene and protein expression of 
collagen I, a-SMA, and TGF-β
Antifibrotic small molecule AA-5  
downregulated gene and protein  
expression of a-SMA and collagen I and 
decrease in cell stiffness
[243]
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significantly reduced directed cell migration under aligned 
fiber culture conditions.[147] Another study utilized glass slides 
coated with aligned fibers to investigate alignment and migra-
tion of lung fibroblasts isolated from SSc patients. The results 
indicated that migration took place when lung fibroblasts were 
cultured on aligned collagen following stimulation with PDGF, 
but was not induced on the woven, randomly orientated col-
lagen substrates.[148] In addition, heparin, which binds ligands 
including PDGF and stem cell factor (SCF), and imatinib, 
which blocks downstream tyrosine kinase receptors, both 
inhibited lung fibroblast migration individually. Importantly, 
the two drugs showed synergistic effect in SSc cells, supporting 
a possible pilot evaluation of combination therapy.[148] A recent 
study investigated the effect of collagen microarchitecture on 
myofibroblast differentiation and fibrosis. Adipose stromal cells 
(ASCs) were cultured on collagen gels consisting of networks 
with thin fibers and low porosity, or scaffolds with thicker 
collagen fibers with larger pores. Interestingly, ASCs contrac-
tility on collagen matrices with thicker fibers and larger pores 
resulted in collagen fiber densification and alignment in the 
direction of cell polarization and migration, increasing stiffness 
in a physiologically relevant regime of strain. The stiffening of 
local matrix, in turn, stimulated a contractile phenotype via a 
positive feedback loop, thereby modulating myofibroblast dif-
ferentiation and fibrosis.[149] Due to the interaction between 
increased ECM alignment and the formation of fibrotic lesions, 
it is of considerable interest to further investigate the influence 
of patterned cell culture substrates on tissue mechanics and 
collagen alignment.
7.3. Macromolecular Crowding
The recapitulation of collagen matrix formation in vitro has 
proven challenging, partly due to the omission of important 
cofactors in the culture media and partially because of sub-
optimal cell culture conditions. The omission of ascorbate in 
cell culture results in minimal production and deposition of 
collagen within the cell layer. Ascorbic acid is a crucial cosub-
strate for the enzymes prolyl hydroxylase and lysyl hydroxylase, 
which are responsible for the posttranslational hydroxylation 
of prolyl and lysyl residues on collagen fibers. Hydroxylation 
of the prolyl residues renders the collagen triple helix ther-
mostable and hydroxylation of the lysyl residues is respon-
sible for the extracellular cross-linking of collagen fibers.[150] 
However, even with ascorbate supplementation, cells deposit 
Figure 4. Matrix stiffness and mechanotransduction in fibrosis. Mechanotransduction pathways mediate matrix stiffness-induced myofibroblast acti-
vation. Stiffness-mediated traction forces are transmitted across integrins, which induce actomyosin cell contractility mediated by focal adhesion 
kinase (FAK) and RHO-associated kinase (ROCK). These signals activate the downstream effectors YAP (Yes-associated protein), TAZ (transcriptional 
coactivator with PDZ-binding motif) and myocardin-related transcription factor (MRTF), which increase the expression of profibrotic markers such as 
α-SMA and collagen type I. Increased collagen deposition and crosslinking further increases ECM stiffening, creating a profibrotic positive feedback 
loop between matrix stiffness and myofibroblast activation. Created with BioRender.com.
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only subphysiological amounts of secreted collagen I into 
their matrices. Indeed, in standard cell culture settings, the 
conversion of water-soluble procollagen to insoluble collagen 
is relatively slow, since the proteinases required for the enzy-
matic cleavage of procollagen are dispersed in dilute cul-
ture media.[151] To overcome this limitation, macromolecular 
crowding (MMC) has been introduced as a means to accel-
erate ECM deposition in vitro. The addition of macromol-
ecules into the culture media emulates the naturally crowded 
in vivo milieu, and thus amplifies deposition of cell-secreted 
ECM.[152] The addition of macromolecules to the culture media 
also results in a more efficient volume occupancy, preventing 
the dispersion of active molecules, consequently accelerating 
the conversion of procollagen to collagen and ultimately depo-
sition of the latter.[153] Moreover, use of MMC has been dem-
onstrated to drive the molecular assembly of collagen fibrils 
in vitro and to stabilize the formed matrix through enzymatic 
crosslinking.[154] One application of MMC to produce the full 
deposition of collagen in fibroblast cultures has been the devel-
opment of a valuable screening tool, the so-called “Scar in a 
Jar”, for antifibrotic compound screening.[155] The original scar 
in a jar model consisted of human fibroblasts cultured in the 
presence either of 500 kDa dextran sulphate (DxS) or a mix-
ture of neutral 70 and 400 kDa Ficoll (Fc). Crowding of culture 
medium with dextran sulphate served as the rapid deposition 
mode as it yielded maximum granular deposition of collagen I 
by 48 h, whereas neutral mixed Ficoll served as the accelerated 
mode (Fc), which resulted in the deposition of a fibrillar col-
lagen meshwork after 6 d of culture in comparison with non-
crowded cultures.[156] This system has been used to evaluate 
the potential of antifibrotic compounds effective at the epige-
netic, post-transcriptional/translational level. Another study 
utilized the principle of macromolecular crowding to create an 
ECM-rich in vitro hypertrophic scar model that more closely 
recapitulates “in vivo-like” conditions than customarily used 
monolayer culture systems.[157] This model was used to test the 
antifibrotic effect of a series of naphthalene derivatives derived 
from medicinal herbs on human dermal fibroblasts. Interest-
ingly, shikonin and naphthazarin were shown to inhibit the 
transcription and translation of collagen in human scar-derived 
fibroblasts and induced apoptosis via the mitochondrial apop-
tosis pathways, suggesting their potential therapeutic value 
for the treatment of dermal fibrosis and scarring.[157] A sim-
ilar study, combined macromolecular crowding with TGF-β to 
develop a robust, high throughput, phenotypic screening assay 
using pulmonary fibroblasts derived from patients affected by 
idiopathic pulmonary fibrosis.[158] The Scar-in-a-Jar offers a 
novel pathophysiologically relevant screening and evaluation 
tool for antifibrotic compounds interfering with different key 
steps in the collagen biosynthesis pathway.
Overall, despite all these progresses in the modeling of 
fibrosis using MMC in vitro, the importance of the crowded 
extracellular niche is still underestimated,[159] likely due to the 
fact that optimal crowding agents remain still elusive and fur-
ther studies are required to reveal and unravel their diverse 
effects on cell behavior and phenotype. Optimization of MMC 
protocols will contribute to the generation of models with high 
levels of biomimicry which can be used as an instrument to 
recreate SSc conditions.
7.4. Dimensionality and 3D Architecture
Cell-based assays have been crucial in drug discovery and pro-
vide a simple, rapid, and cost-effective tool to support screening 
of therapeutics before large-scale and cost-intensive animal 
testing. To date, the majority of cell-based assays are based on 
traditional 2D monolayer cultures grown on flat dishes opti-
mized for cell attachment and growth.[160] However, 2D culture 
systems have multiple limitations, including loss of tissue-spe-
cific architecture, non-physiological mechanical and biochem-
ical signals, and non-physiologic cell-to-cell and cell-to-matrix 
interactions.[161] The standard 2D environment may therefore 
provide misleading results regarding the predicted responses 
of cells to drug treatments (Figure  5).[162] To overcome these 
important limitations, there has been tremendous progress in 
tissue engineering and regenerative medicine over the past few 
decades that has led to the development of a wide range of 3D 
cell culture systems. Indeed, multicellular organisms reside 
within a complex 3D environment, rich with multiple ECM 
components, several cell populations and soluble factors, which 
not only provide structural support to tissues and organs, but 
also physiological conditions that allow for optimal function-
ality and delineate specific microenvironments.[163] Table  4 
summarizes several 3D scaffold-free and scaffold-based SSc 
models, including the therapeutic approaches used to evaluate 
each model’s feasibility for drug development and screening.
7.4.1. Self-Assembled Models
Tissues are formed by building blocks that self-assemble into 
highly organized structures that enable and regulate their func-
tions.[164] Tissue engineering by self-assembly (TESA) relies on 
the inherent capacity of cells to self-assemble into highly organ-
ized 3D tissue-like constructs and to produce their own ECM, 
without the need of an external scaffold. These assemblies can 
be created through self-assembled aggregation, cell sheets, 
tissue strands or direct bioprinting.[165]
3D cell aggregates allow for the fabrication of organotypic 
microtissues due to their multidimensional cell–cell interac-
tions and communication. Multicellular spheroids are scaf-
fold-free cellular models based on the spontaneous aggrega-
tion of cells into spherical compact clusters on nonadherent 
substrates. The complex cell interactions recapitulate spatial 
and functional characteristics of the native tissue modulating 
cell activities and signaling.[166] For this reasons, 3D multicel-
lular spheroids have been utilized as in vitro models of fibrosis. 
Recently, 3D human fibroblasts spheroids have been created 
for the development of an in vitro fibrogenesis model. Fibro-
blast-based spheroids showed significantly higher expression 
levels of fibrotic genes (αSMA and collagen I) compared to 2D 
monolayer culture. Furthermore, since the absence of immune 
cell mediators was recognized as a likely limit to physiologic 
model behavior, hybrid spheroids were fabricated with fibro-
blasts and macrophages. The addition of macrophages to the 
fibroblasts spheroids at a ratio of 1:16 (macrophages-fibroblasts) 
resulted in an increase of fibroblast activation and myofibro-
blast differentiation. Similarly, more macrophages were polar-
ized toward an inflammatory type M1 in this group with greater 
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CCR7 and pSTAT1 expression. In addition, hybrid spheroids 
demonstrated high expression of fibrosis-related genes (col-
lagen I, collagen III and TGF-β) and inflammatory genes (TNF, 
IL-1β and IL-6). This system thus represents a valuable in vitro 
fibrogenesis model for high-throughput antifibrosis therapy 
screening.[167] Building on the success of spheroids, researchers 
have also focused on organoids, which generally better replicate 
tissue morphology and organization, and embed multiple cell 
populations that are distributed physiologically.[168] Organoids 
are in vitro self-assembling 3D organ-like architectures grown 
from tissue-specific adult stem cells or pluripotent stem cells, 
such as embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs).[169] Organoids have been engineered to 
model pathogenetic mechanisms that affect lung homeostasis 
and involve complex interactions between different cell types, 
such as those occurring in interstitial lung diseases, which is 
a frequent complication of systemic sclerosis.[170] For instance, 
lung organoids composed of iPSC-derived mesenchymal cells, 
treated with exogenous TGF-β1, demonstrated increased con-
traction and the development of fibroblastic foci by expressing 
of collagen 1 and α-SMA.[171] Organoids represent valuable tools 
for the screening of compounds with pro-regenerative, antifi-
brotic or tissue protective capabilities for precision medicine. 
However future applications of organoids may be limited by the 
fact that they lack mechanical cues, vasculature, and immune 
components, and may be prone to tumorigenicity in case of 
IPSCs.
Another strategy to fabricate cellular 3D constructs consists 
of stacking of multiple cell sheets, which takes advantage of 
the cell-deposited ECM network that intertwines the different 
cell sheets.[172] Self-assembled reconstructed dermis equivalents 
have been created to study the fibrotic phenotype of SSc fibro-
blasts. Fibroblasts isolated from lesional or nonlesional skin of 
early- and late-stage SSc patients were grown for 35 d to form 
sheets and two fibroblast sheets were layered and maturated to 
generate a thick dermal-like layer.[173] The study showed that in 
this system, development of skin fibrosis resulted in progres-
sive changes at the fibroblast level, from a normal phenotype 
to a sustained and autonomous fibrotic phenotype. Based on 
these results, the authors suggested that antifibrotic treatments 
of SSc could gain efficacy if they were tailored to disease dura-
tion and severity. Another study developed a tissue-engineered 
model of self-assembled reconstructed skin to mimic interac-
tions between dermal and epidermal cells.[174] Four dermal 
fibroblasts layers were superimposed to form a reconstructed 
dermis and undifferentiated, differentiated and unsorted 
keratinocytes were seeded onto the dermal sheets. Results 
showed that undifferentiated keratinocytes inhibited dermal 
fibrosis through downregulation of TGF-β, induction of FGF-β 
(fibroblasts growth factor β) and initiation of desmosome for-
mation, indicating that undifferentiated keratinocytes may be a 
promising option for fibrotic scar prevention. Despite the utility 
of self-assembled skin models for disease modeling, these 
systems lack the presence of critical components such as hair 
follicles, glands, tactile corpuscles, and subcutaneous adipose 
tissue, which play a critical role in physiological functioning. 
However, progress in biofabrication techniques will likely 
address the incorporation of such appendages.[175]
7.4.2. Scaffold-Based Models
Scaffold-based models of 3D tissues consist of cells grown in 
the presence of support scaffolds consisting of either hydrogel-
based or polymeric fiber-based materials. These scaffolds 
can be composed of natural, synthetic, or combinations of 
Figure 5. Advantages and limitations of in silico, in vitro, and in vivo models utilized to replicate complex pathophysiologies. Created with BioRender.com.
Adv. Biology 2021, 5, 2000168
www.advancedsciencenews.com
© 2021 The Authors. Advanced Biology published by Wiley-VCH GmbH2000168 (16 of 26)
www.advanced-bio.com
Table 4. 3D in vitro scaffold-free and scaffold-based models of SSc and their application in drug screening (α-SMA, α-smooth muscle actin; DAMPs, 
damage-associated molecular patterns; DFs, dermal fibroblasts; EKs, epidermal keratinocytes; ECM, extracellular matrix; iPSC, induced pluripotent 
stem cell; LOXL-4, lysyl oxidase-like-4; MD-2, myeloid differentiation-2; SAS, self-assembled stromal tissues; TGF-β, transforming growth factor-β; 
TLR4, toll-like receptor-4).




– Early-stage SSc or late-stage 
SSc-derived human DFs
TGFβ-1 induced a significant 





– Normal human EKs and 
DFs
Differentiated keratinocytes  
increased collagen and TGF-β  
gene and protein expression,  
but not undifferentiated  
keratinocytes
– [244]
3D skin organoid – DFs and EKs generated 
from iPSCs derived from 
cord blood mononuclear 
cells (CBMCs)
TGF-β treatment increased the  
thickness and collagen gene  
and protein expression deposition  
of the 3D iPSC-fibroblasts layer
Pirfenidone attenuated the 
increase in the thickness and  
collagen expression
[182]
Tissue spheroids – Human primary  
fibroblasts and human 
macrophages
Fibroblasts in the 3D spheroids 
 had significantly higher expression 
levels of α SMA and collagen I 
compared to the 2D culture. Addition 
of macrophages to the spheroids 
enhanced collagen I maturation
– [167]
Scaffold-based models
3D organotypic human skin 
equivalents
Collagen type I (rat/bovine) 
hydrogel
Human DFs, human  
dermal microvascular 
endothelial cells, foreskin 
keratinocyte human mast 
cell line (HMC-1)
HMC-1 cells induced α-SMA  
expression by fibroblasts and  
stimulated fibroblast contraction  
of collagen gels
Tryptase inhibitors eliminated  
the ability of HMC-1 cells to  
stimulate fibroblast contraction
[245]
Human DFs and EKs Exogenous fibronectin extra  
domain A (FnEDA, 10 µg mL−1)  
had potent effects on collagen gene 
expression, myofibroblast  
differentiation, increased matrix 
stiffness and collagen cross-linking in 
human skin equivalents
RNA interference and  
inhibitor of TLR-4 prevented  
cutaneous fibrosis, collagen 
deposition, and myofibroblast 
accumulation
[246]
Healthy human dermal DFs 
and EKs
TGF-β induced the expression of col-
lagen I, fibronectin and α-SMA in skin 
equivalents
Agonist peptides targeting  
adiponectin receptor abrogated  
the stimulation of fibroblast 
migration, and attenuated fibrotic 
expression in unstimulated SSc 
fibroblasts
[247]
Healthy or SSc-derived DFs SSc fibroblasts progressively  
remodel their dermal  
microenvironment, with  
time-dependent increases in  
collagen deposition, matrix  
reorganization, accumulation of 
DAMPs and substrate rigidity
Inhibitors of MD-2/TLR-4 complex 
formation significantly  
reduced rigidity and collagen  
content of the tissue equivalents
[248]
Healthy or SSc-derived DFs 
and human EKs
SSc-fibroblasts demonstrated 
enhanced stromal rigidity  
with increased collagen  
crosslinking, upregulation of  
LOXL-4 expression and innate 
immune signaling genes
Knockdown of LOXL-4  
suppressed rigidity, contraction 
and α-SMA expression in  
SSc-fibroblasts skin equivalents 
and TGF-β induced ECM  
aggregation and collagen  
crosslinking in SAS
[249]
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different polymers, and represent a 3D construct that is struc-
turally, mechanically and functionally similar to the biological 
tissue.[176,175]
For the fabrication of human skin equivalents, dermal fibro-
blasts are generally cultured in collagen matrices to recreate a 
dermal-like layer, whereas keratinocytes are cultured on top of 
these dermal equivalents, followed by air–liquid interface cul-
ture to promote full epidermal maturation.[177] For example, 
bioengineered human skin equivalents were fabricated using 
both SSc-derived dermal fibroblasts and normal dermal fibro-
blasts.[178] Stromal equivalents were assembled by embedding 
dermal fibroblasts into collagen type I hydrogels. Full skin 
equivalents were fabricated by adding keratinocytes onto the 
collagen gel, after the maturation of the dermal layer. Results 
evidenced that SSc fibroblasts altered collagen architecture, as 
seen by a more mature and aligned fibrillar structure, enhanced 
stromal rigidity with increased collagen crosslinking, and 
upregulated LOXL-4 expression and innate immune signaling 
genes. Interestingly, knockdown of LOXL-4 suppressed rigidity, 
contraction and α-SMA expression in the SSc skin equivalents 
and TGF-β-induced ECM aggregation and collagen crosslinking 
in the stromal compartment. This skin-like tissue platform 
provided a suitable tool to test mechanisms that mediate skin 
fibrosis. Nevertheless, the lack of vascular and immune cells 
into the 3D skin-like tissues limits its potential.
Bioengineered skin equivalents have also been utilized to 
develop skin-humanized mouse models to test the progression 
of SSc and to monitor the response to antifibrotic drugs in vivo. 
For instance, 3D bioengineered skin, based on plasma-derived 
hydrogels and containing human SSc-derived keratinocytes and 
fibroblasts, were grafted onto immunodeficient (SCID) mice. 
Results showed that the human skin-SCID mouse models 
closely replicate the SSc fibrotic phenotype in vivo up to 16 
weeks.[179]
Despite the relevance of cell populations derived from SSc 
patients, the fabrication of 3D tissue equivalents is limited by 
the availability of donor cells. In this regard, human iPSCs 
offer great potential to generate relevant cell types and can 
provide an alternative source of cells for tissue engineering 
purposes.[180] Currently, patient-specific iPSCs are generated by 
reprogramming of adult somatic cells by ectopic expression of 
pluripotency-associated transcription factors including OCT4, 
SOX2, KLF4, and c-MYC.[181]
Cord blood mononuclear cells (CBMCs)-derived iPSCs have 
been used to generate dermal fibroblasts, which have been used 
to create 3D dermal equivalents. Treatment with TGF-ß1 acti-
vated iPSC-fibroblasts and increased their proliferation rate and 
ECM production. In addition, TGF-β1 treatment increased the 
thickness of the 3D iPSC-fibroblasts construct. Treatment with 
pirfenidone, a drug used to treat idiopathic pulmonary fibrosis, 
elicited an antifibrotic effect, attenuating the increase in dermal 
thickness and expression of fibrosis genes. These results sug-
gest that the use of iPSC-derived fibroblasts in skin equivalents 
could be utilized for drug screening purposes.[182]
A simple and versatile technique used for the fabrication 
of ECM-mimicking fibrous scaffolds is electrospinning. Elec-
trospun fibrous scaffolds create nano- to microscale fibrillar 
network with interconnecting pores, resembling natural ECM 
in tissues, and facilitating the formation of artificial tissues 
in vitro.[183] Poly-caprolactone (PCL) electrospun scaffolds 
coated with bleomycin treated lung extracts, obtained from 
solubilization with a glass homogenizer, have been used as a 
model of idiopathic pulmonary fibrosis (IPF) to induce bone 
marrow-derived cells to differentiate into myofibroblast-like 
cells.[184] This approach combines biological extracts isolated 
from fibrotic lungs with synthetic nanofibers that serve as an 
ECM-like substrate to determine the effect of biochemical sig-
nals present in the fibrotic microenvironment. This model has 
the potential to help identify compounds that either mitigate 
or reverse the fibrotic differentiation of bone marrow -derived 
cells. Moreover, bone marrow-derived cells cultured on electro-
spun fibers with higher elastic modulus displayed increased 
fibrotic gene expression, demonstrating the importance of 
matrix modulus in cell differentiation.[184]
The design of electrospun scaffolds with appropriate topo-
graphical features is critical to determine cell function and to 
foster desired cell differentiation. For example, a recent study 
showed that nanometer scale electrospun fibers upregulated 
Model Scaffold Cells Experimental output Therapeutic Refs.
Vascularized human skin 
equivalents
Decellularized segment  
of porcine jejunum  
supplied by a single artery-
vein pair with intact outer 
vascular system
Human EKs, DFs and 
microvascular  
endothelial cells
Skin equivalents perfused at a  
physiological pressure formed  
a functional vessel system.  
Exposure to TGF-β induced  
fibroblast to myofibroblast  
transition, increased release of  
collagen and excessive deposition of 
extracellular matrix
Nintedanib attenuated TGF-β 
signaling, reduced fibroblast 
to myofibroblast transition and 
decreased ECM deposition
[199]
Decellularized scaffold Decellularized scaffolds 
prepared from healthy and 
fibrotic scleroderma lung 
explants
Healthy and SSC-derived 
peripheral blood  
mononuclear cells  
(PBMCs)
Scleroderma scaffolds increased  
procollagen type I production  
by PBMCs, which was stimulated  
by enhanced stiffness and  
abnormal ECM composition. 
Enhanced Netrin-1 expression was 
seen on SSc-derived cells
Antibody mediated netrin-1  
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the expression of α-SMA, TGF-β, and vimentin filaments in 
comparison to micrometer scale fibers. The size change of the 
electrospun fibers (from micrometers to nanometers) altered 
fibroblast differentiation and led to higher α-SMA expression 
and more contractile myofibroblasts.[185] Another study dem-
onstrated that electrospun fiber diameter can modulate epithe-
lial to mesenchymal transition (EMT). Indeed, epithelial cells 
grown on fibers with an average diameter of 5µm exhibited 
a downregulation of epithelial markers such E-cadherin and 
upregulation of mesenchymal markers such as vimentin. How-
ever, cells grown on fibers with an average diameter of 0.5 µm 
grew as compact colonies with a stable epithelial phenotype.[186]
Despite considerable advances in biomaterials design and 
development for the engineering of physiological-relevant 
tissue models, several challenges hinder the applicability of 
such models as part of daily pharmaceutical research. One such 
limitation is the scalability and manufacturing of complex, bio-
mimetic and reproducible scaffold-based models in compliance 
with current good manufacturing practices (cGMPs), which 
result in cost-intensive processes, not comparable to 2D and 
self-assembled models.
7.4.3. Decellularized Matrix Bioscaffolds
Given the complexity of ECM composition and structure, 
designing and fabricating a biomaterial-based scaffold that fully 
mimics the biochemical and structural properties of native 
tissue ECM is currently challenging. However, decellularization 
of whole tissues and organs by removing cellular components 
provides a useful method for harvesting an ECM which retains 
tissue- specific 3D morphology, biochemical, and biomechanical 
cues.[187,163a] A 3D model of the fibrotic lung microenvironment 
created from decellularized lung explants was used to deter-
mine whether the lung ECM of patients with scleroderma leads 
to the development of fibrocytes from peripheral blood mon-
onuclear cells. Fibrocytes are collagen-producing leukocytes 
abundantly present in patients with SSc-related interstitial lung 
disease (ILD) via unknown mechanisms that have been asso-
ciated with altered expression of neuroimmune proteins. Cul-
ture of control cells and patient-derived cells in lung scaffolds 
from patients with SSc-related ILD increased production of 
procollagen I, which was stimulated by enhanced stiffness and 
abnormal ECM composition. Moreover, enhanced detection of 
netrin-1 (a laminin-like protein that regulates cell–matrix inter-
actions) expression in cells from patients with SSc-related ILD 
was observed, and antibody-mediated netrin-1 neutralization 
attenuated detection of collagen-producing leukocytes in all set-
tings.[188] This study demonstrated the utility of decellularized 
platforms for disease modeling and potential drug discovery. 
Other studies provided insights into ECM-mediated positive-
feedback loops using decellularized lung scaffold from patients 
with IPF.[189] In the absence of exogenous factors, IPF ECM 
alone can promote normal lung fibroblasts to become activated 
myofibroblasts, and once fibroblasts are activated, IPF ECM 
sets up a positive feedback loop capable of sustaining progres-
sive fibrosis. Although successful decellularization has been 
achieved for many organs, standardized decellularization pro-
tocols still need to be defined with the final goal of advancing 
the creation of in vitro models.[190] Moreover, the development 
of decellularized skin matrices will allow further exploration in 
the pathogenesis of SSc dermal fibrosis.
7.4.4. Organ on Chip
Recent advances in microfabrication and microfluidics have 
enabled the development of microengineered models of human 
organs—known as organs-on-chips—that have the potential to 
provide platforms to model organ level responses for drug dis-
covery in an in vitro setting.[191] Important cues involved in the 
pathogenesis of fibrosis, such as mechanical strain, fluid flow, 
and hydrostatic pressures, can be integrated in such models. 
Recently, a 3D-bioengineered pulmonary fibrotic (Eng-PF) 
tissue was developed utilizing silk collagen-I hydrogels seeded 
with pulmonary fibroblasts, airway epithelial cells, and micro-
vascular endothelial cells. Eng-PF tissue was cultured under 
tension, tethered along the longitudinal axis of a bioreactor 
plate, and had the capacity to be cyclically strained with perfu-
sion ability. Eng-PF tissues were able to model myofibroblast 
differentiation and permit evaluation of antifibrotic drugs, 
such as pirfenidone and nintedanib. Further, Eng-PF tissues 
were used to model epithelial injury with the addition of bleo-
mycin and cellular recruitment by perfusion of cells through 
a hydrogel microchannel.[192] Unlike other 3D tissue systems, 
lung-on-chip platforms are standalone devices, therefore scaling 
these devices for high throughput antifibrotic drug screening 
could be challenging. Organ-on-chip technologies have also 
been advanced in the production of skin equivalents. The main 
advantages supported by microfluidics are the presence of fluid 
flow and fine control of the microenvironment, which yield 
improved epidermal morphogenesis and differentiation, and 
enhanced barrier function.[193] Although a skin-on-a-chip model 
consisting of epidermal, dermal and endothelial cells has been 
used to stimulate skin inflammation and edema,[194] a skin chip-
model that replicate dermal fibrosis still needs to be developed.
8. Missing Players: Vasculature and 
Hematopoietic Immune Cells
Recent research has enabled the development of in vitro models 
which recapitulate different aspects of SSc, which could signifi-
cantly contribute to early-stage drug discovery. However, current 
bioengineered systems often lack the presence of perfusable 
(micro-) vasculature and organ-specific immune responses, 
which need to be incorporated into the tissue models to achieve 
patho-physiologically relevant levels of function.
It is known that patients affected by SSc present a series of 
vascular abnormalities. Among them are direct damage of vas-
cular and perivascular cells, abnormal vasoreactivity, hypoxia, 
impaired angiogenesis, and platelet dysfunction. These vas-
cular changes result in decreased capillary blood flow, and 
subsequently in clinically overt symptoms such as Raynaud’s 
syndrome and fingertip ulcers.[195] In addition, vascular damage 
contributes to the production of a cascade of soluble mediators 
that ultimately influence the onset and progression of tissue 
fibrosis.[196]
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Given the importance of the vasculature in SSc, the integra-
tion of vascular structures into in vitro cultured tissues is of 
paramount importance to provide realistic models of complex 
interactions, which modulates tissue remodeling and fibrosis 
in the tissue of interest.
One common strategy relies on the spontaneous organiza-
tion of endothelial cells to form vascular networks within bio-
materials scaffold or in multicellular assemblies.[197] Initially, 
endothelial cells form a primitive network within an avascular 
tissue, which is similar to vasculogenesis. In order to matu-
rate into a functional vascular network with sufficient vascular 
cell viability and function, perfusion bioreactors are required 
to mimic in vivo like flow rate.[198] For example, a recent study 
focused on the development of vascularized skin equivalents 
as an advanced model of human skin with a fully polarized 
epidermal layer, a stratified dermis and a functional vascular 
system with physiological perfusion pressures.[199] These 
models were induced to undergo fibrotic transformation and 
resembled key features of SSc skin, with accumulation of ECM, 
fibroblast to myofibroblast transition and aberrant activation 
of TGF-β signaling. In addition, treatment with nintedanib in 
a pharmacologically relevant dose exerted antifibrotic effects 
in vascularized human skin equivalents by attenuating TGF-β 
signaling, reducing fibroblast to myofibroblast transition and 
decreasing ECM deposition.[199] By incorporating a mature vas-
cular network, this platform provided a pathophysiologically 
relevant human setting for the evaluation of antifibrotic drugs, 
potentially improving predictive value.
Considering that the immune system plays a pivotal role in 
this disease,[200] another key element which is generally missing 
during the development of in vitro tissue analogues is the pres-
ence of relevant immune cells. Activation of both innate and 
adaptive immune responses leads to activation of fibroblasts, 
differentiation into myofibroblasts, ECM deposition and finally 
fibrosis. Monocytes, macrophages and dendritic cells all release 
soluble mediators that can directly affect fibroblast activation 
and tissue remodeling, or indirectly affect it by inducing the 
release of profibrotic factors by other cell types, including T 
cells and B cells.[18]
Using cocultures of immune cells with fibroblasts, a number 
of valuable in vitro models have tried to approximate the role 
of innate/adaptive immunity activation in fibroblasts differen-
tiation and organ fibrosis. For example, it was demonstrated 
that coculture of SSc fibroblasts and SSc plasma-differentiated 
macrophages (expressing high levels of CCL2, IL-6, and TGF-β) 
using transwell plates resulted in activation of signaling path-
ways involved in the regulation of inflammation and fibrosis, 
suggesting that therapeutic targeting of these cells may be 
beneficial in ameliorating SSc progression.[201] Another study 
demonstrated that B cells cocultured with human dermal fibro-
blasts (HDFs) derived from SSc patients are potent inducers of 
IL-6, CCL2, and TGF-β1, which enhance collagen production 
by fibroblasts.[202] The integration of key immune cell subsets 
is likely a needed strategy to improve the relevance of SSc in 
vitro models. However, the complex mechanisms by which 
the immune system orchestrates organs and tissues are chal-
lenging to replicate, especially in prolonged culture conditions. 
New approaches such as “on-a-chip” platforms can incorpo-
rate multiple cell types under controlled biochemical and 
biophysical conditions contributing to the formation and pro-
gression of SSc.[203]
9. Challenges and Future Directions
Among autoimmune diseases, SSc is one of the most devas-
tating pathologies, and its heterogeneity and complexity pose 
unique challenges for the discovery and development of effec-
tive therapeutic strategies. Although tremendous scientific pro-
gress has significantly increased the knowledge of the biological 
and molecular mechanism at the basis of SSc, numerous unan-
swered questions remain in the field of SSc therapeutics. 
Animal models represent indispensable for preclinical drug 
testing, even though none of these models faithfully recapitu-
lates the full spectrum of SSc. For this reason, the development 
of in vitro models that replicate the complex and dynamic SSc 
milieu are essential to overcome some of the in vivo disease 
models’ shortcomings. As herein reviewed, a variety of biolog-
ical, biochemical, and biophysical cues have integrated into in 
vitro platforms to mimic the pathophysiological signals typical 
of SSc, thereby improving their suitability for the identification 
and screening of effective drugs. However, in vitro models have 
not yet fully recovered the SSc phenotype to a level comparable 
with the human disease. Due to the complexity of SSc, it is likely 
unrealistic to create models that fully embrace all aspect of the 
pathology, including vascular component, immune system and 
organ fibrosis. Multifactorial approaches combining synergistic 
microenvironmental cues are one way forward to develop more 
complex in vitro systems. Advancements in biomaterial sci-
ence will contribute to the development of new platforms that 
not only give structural dimensionality to the models, but will 
also modulate cell behavior by providing heterogeneous spa-
tial organization and spatiotemporal controlled biological and 
mechanical signals.[204] Progress in iPSCs technologies have 
the potential to provide disease-relevant cells in a personalized 
manner and could facilitate the development of patient-specific 
SSc models for personalized medicine without requiring mul-
tiple tissue collections.[205]
Emerging technologies that go beyond well-established ex 
vivo assays for the characterization of fibrotic hallmarks (SDS-
PAGE,[206] quantification of hydroxyproline content,[206] Sircol 
collagen assay,[207] histological and immunohistological anal-
ysis), not only help to better understand the biology of the dis-
ease, but also lead to improved assessment of the therapeutic 
effects of potential drug candidates. Examples include assess-
ment of ECM structure and stiffness by second harmonic gen-
eration (SHG) microscopy[208] and atomic force microscopy,[145] 
as well as noninvasive imaging of tissue and organ damage[209] 
by magnetic resonance imaging (MRI),[210] computed tomog-
raphy (CT),[211] ultrasound (US),[212] and positron emission 
tomography (PET).[213] These imaging techniques can be readily 
utilized to measure treatment responses over time without the 
need to sacrifice experimental animals, thereby facilitating the 
clinical translation of antifibrotic therapies.
Overall, despite the wide recognition of the utility and poten-
tial of 3D models in the drug development pipeline, there is 
not substantial evidence that such systems outweigh the data 
obtained from 2D models or the cost of testing in animals. 
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Indeed, drug discovery programs are still far from being driven 
by primary screens in 3D and it is still premature to claim that 
3D models improve the clinical success rates of drug candi-
dates. In addition, the majority of models are conventionally 
not designed for automated analyses, being incompatible with 
high-content screening platforms, and thus are held back by 
routine applications into industrial settings. Therefore, future 
efforts should be directed not only to the standardization and 
validation of such models, but also to their miniaturization in 
order to enhance experimental efficiency with automation.
While further advances are needed, in vitro models of SSc 
represent promising platforms for disease modeling and for 
drug discovery, increasing our understanding of the mecha-
nisms underlying this devastating disease.
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